Long Predicted Medicaid Specialty Drug Trend Finally Surpasses 50% of Pharmacy Spend in the Latest Magellan Rx Management Medicaid Pharmacy Trend Report
15 Noviembre 2021 - 5:30AM
Business Wire
Magellan Rx Management, the full-service pharmacy benefits
management division of Magellan Health, Inc. (NASDAQ: MGLN),
released its sixth annual Medicaid Pharmacy Trend ReportTM, the
industry's leading report exclusively detailing trends in the
Medicaid pharmacy fee-for-service (FFS) space.
The Medicaid Pharmacy Trend Report highlights the evolving
landscape of Medicaid, made even more dynamic from the events of
the last two years. The report includes an in-depth analysis of
class and drug trends, forecasting of Medicaid key conditions,
drugs in the pipeline, and Medicaid pharmacy economics. This is
also the only detailed industry source for the analysis of Medicaid
pharmacy fee-for-service (FFS) gross, net, and forecasted drug cost
trends.
"As our nation continues to navigate the lasting impacts of the
COVID-19 pandemic, there is no doubt that states are facing
unprecedented challenges across all areas of government, especially
related to ensuring the mental and physical well-being of their
citizens," said Meredith Delk, PhD, MSW, general manager and senior
vice president, government markets, Magellan Rx Management. "The
Medicaid Trend Report illustrates critical data-driven observations
and solutions. The valuable insights in this report can assist
states on their mission to ensure a high quality and cost-effective
prescription drug program for their most vulnerable
populations."
Key findings in this year's report include:
- In 2020, specialty drugs accounted for 51.4% of the net cost in
Medicaid, a trend predicted for the last five years. A constant
imbalance in spend, specialty drugs only accounted for 1.3% of
utilization.
- 2020 traditional net cost trend for Medicaid FFS was positive
for the first time in five years with the introduction of
new-to-market drugs.
- Medicaid FFS top drug classes remained almost identical to
previous years – with HIV/AIDS and antipsychotics accounting for
more than 19.8% of the total net drug spend.
- With a steady increase in pipeline drugs, most key conditions
will experience increased trend over the next three years.
Comparatively, conditions with generic drug introductions or
specialized management strategies will see a decrease.
Many of the Medicaid FFS drug trends remained steady, but the
drug pipeline, a concern for all lines of business and operating in
a year unlike any other, forced states to consider alternative
pathways to continuity of care for patients, largely focused on
technology-based solutions.
"Our ability to offer comprehensive and configurable solutions
that fundamentally connect the dots for our customers and their
members around the efficacy of drugs, quality care and payments is
key," said Delk.
The Magellan Rx Management Medicaid Pharmacy Trend Report
includes data from Magellan Rx's Medicaid FFS pharmacy programs in
25 states and the District of Columbia. The material is reviewed
and supported by a team of Magellan Rx experts with broad national
expertise, including 369 years of combined pharmacy benefit
administration (PBA) experience.
About Magellan Rx Management: Magellan Rx Management, a
division of Magellan Health, Inc., is shaping the future of
pharmacy. As a next-generation pharmacy organization, we deliver
meaningful solutions to the people we serve. As pioneers in
specialty drug management, industry leaders in Medicaid pharmacy
programs and disruptors in pharmacy benefit management, we partner
with our customers and members to deliver a best-in-class
healthcare experience.
About Magellan Health: Magellan Health, Inc., is a leader
in managing the fastest growing, most complex areas of health,
including special populations, complete pharmacy benefits and other
specialty areas of healthcare. Magellan supports innovative ways of
accessing better health through technology, while remaining focused
on the critical personal relationships that are necessary to
achieve a healthy, vibrant life. Magellan's customers include
health plans and other managed care organizations, employers, labor
unions, various military and governmental agencies and third-party
administrators. For more information, visit MagellanHealth.com.
(MGLN-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211115005141/en/
Media: Lilly Ackley, ackleyl@magellanhealth.com, (860)
507-1923 Investor: Darren Lehrich,
lehrichd@magellanhealth.com, (860) 507-1814
Magellan Health (NASDAQ:MGLN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Magellan Health (NASDAQ:MGLN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024